Seoul, South Korea, and London, UK: 5 September 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) announces that positive survival data from a recently completed trial of ASA404 are presented today at the World Conference on Lung Cancer in Seoul, South Korea. This single-arm phase II trial evaluated an 1800 mg/m2 dose of ASA404 in combination with carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer. Key findings were as follows:
